Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medivation and Astellas are planning to begin a Phase III clinical trial of enzalutamide in men with high-risk, hormone-sensitive, non-metastatic prostate cancer.
Subscribe to our email newsletter
The trial is designed to assess the efficacy and safety of enzalutamide in patients with prostate cancer that has biochemically recurred following definitive local therapy with radical prostatectomy and/or radiation therapy.
Currently there is no prescription medicine specifically approved for patients with prostate cancer in the US.
Around 1,860 patients will be enrolled in the randomized, multi-national Phase III trial, which will be conducted at about 160 sites.
In the trial, patients will be randomized into three separate groups: enzalutamide plus leuprolide acetate, enzalutamide monotherapy, or placebo plus leuprolide acetate.
Medivation chief medical officer Dr Lynn Seely said: "It is estimated that approximately one third of men in the US experience a rising PSA, also known as biochemical recurrence, after localized therapy for the treatment of prostate cancer.
"This trial will determine if enzalutamide can delay the development of metastatic prostate cancer in high-risk men with a rapidly rising PSA.
"The initiation of this trial in collaboration with our partner Astellas showcases our mutual commitment to continue exploring the potential of enzalutamide in areas of significant unmet medical need."
The trial will evaluate enzalutamide at a dose of 160mg to be taken orally once daily and leuprolide acetate will be given as an injection of 22.5mg once every 12 weeks for a minimum of three doses.